Regeneron Reports Q3 2026 Financial Results, Expanded Sanofi Collaboration, and FDA Approval of Pasatru

Regeneron reported Q3 2026 revenue of $5.1 billion, up 36% year over year, and non-GAAP EPS of $20.07, both above analyst expectations; Dupixent, EYLEA HD and Libtayo posted record net sales. The company expanded its Sanofi alliance to cover four long-acting immunology antibodies, receiving $1.0 billion upfront and becoming eligible for up to $7.0 billion in future milestones. The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, while Regeneron said its pipeline includes about 50 candidates advancing across therapeutic areas.